Regenerative Medicine Market

Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), Product (Cell-Based, Acellular), Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology) - Forecast to 2021

Report Code: BT 4419 Feb, 2017, by marketsandmarkets.com

[137 Pages Report] The Regenerative medicine market is expected to reach USD 38.70 billion by 2021 from USD 13.41 billion in 2016 at a CAGR of 23.6%. The cell-based products is expected to dominate the global Regenerative Medicine market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies are driving the growth of the cell therapy segment.

Market Dynamics

Drivers

  • Government & Private Funding to Support the Development of Regenerative Medicine
  • Rising Prevalence of Chronic Diseases and Genetic Disorders
  • Increase in Global Healthcare Expenditure
  • Rapid Growth in the Aging Population
  • Increase in Corporate Partnerships to Accelerate Development and Commercialization of Regenerative Medicine

Restraints

  • Ethical Concerns With the Use of Embryonic Stem Cell for R&D
  • Lack of Clear Regulatory Guidelines

Opportunities

  • Rising Demand for Organ Transplantation
  • Strong Product Pipeline

Orthopedic & Musculoskeletal Disorders application will drive the growth of regenerative medicine market

Based on therapy, the Regenerative medicine market is segmented into cell therapy, gene therapy, tissue engineering, and immunotherapy. Immunotherapy is the fastest growing segment in the global Regenerative Medicine market, during the forecast period. This market is also segmented by application. By application, the segments are orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications.  Oncology is the fastest growing application market in the global Regenerative Medicine market in 2016.
The objectives of this study are as follows:

  • To define, describe, and forecast the global regenerative medicine market on the basis of therapy, product, application, and region
  • To provide detailed information regarding major factors influencing market growth (drivers, restraints, and opportunities)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze competitive developments such as product launches, collaborations, agreements, partnerships, expansions, and acquisitions in the global regenerative medicine market

Research Methodology

Top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation-by product, therapy, application, and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources have been used to identify and collect information useful for this extensive commercial study of the regenrative medicine market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the regenerative market. The breakdown of profiles of primaries is shown in the figure below:

Regenerative Medicines Market

To know about the assumptions considered for the study, download the pdf brochure

The key players in the cell-based products segment are Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

Target Audience for this Report:

  • Healthcare providers & clinical experts
  • Service providers
  • Therapeutic companies
  • Contract manufacturers
  • Academic research institutes

Major Market Developments:

  • In February 2016, Acelity (U.S.) partnered with Mediq (Netherlands), a leading homecare and medical device delivery company. Under the terms of this agreement, Mediq will distribute Acelity’s advanced wound care and regenerative medicine portfolio in Denmark, Finland, Norway, and Sweden.
  • In June 2014, Vericel Corporation (formerly known as Aastrom Biosciences, Inc.) Aastrom completed the acquisition of Sanofi's (France) Cell Therapy and Regenerative Medicine (CTRM) business for USD 4 million in cash and USD 2.5 million in a promissory note. This helped Vericel to increase its product portfolio.
  • In November 2015, Osiris Therapeutics, Inc. launched Stravix, a cryopreserved human placental tissue, specifically designed to address surgical needs for soft tissue repair.
  • In July 2015, Integra LifeSciences Corporation completed the acquisition of TEI Biosciences Inc. (U.S.) and TEI Medical Inc. (TEI, U.S.). Through these acquisitions, the company built a strong pipeline of regenerative products, thus accelerating its overall growth.

Scope of the Report:

This report categorizes the Regenerative medicine market into the following segments:

  • Regenerative medicine Market, by Type
  • Cell-based products
  • Acellular products
  • Regenerative medicine Market, by Therapy
  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Immunotherapy
  • Regenerative medicine Market, by Application
  • Orthopedic & Musculoskeletal Disorders
  • Dermatology
  • Cardiology
  • Diabetes
  • Central Nervous System Diseases
  • Other Applications (ocular, autoimmune, dental/oral, and rare diseases)

Regenerative medicine Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • RoE
  • Asia-Pacific
  • Rest of the World (RoW)

Customization Options:

  • Company Information: Detailed company profiles of five or more market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

The global Regenerative medicine market is expected to reach USD 38.70 billion by 2021 from USD 13.41 billion in 2016 at a CAGR of 23.6% from 2016 to 2021.  This market is segmented based on types, therapy, application, and regions.

A number of factors, such as the government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population are expected to drive the growth of this market. However, entry of new players and product failures and recalls are expected to challenge the market growth.

The global Regenerative medicine market is segmented into two types, namely, cell-based products and acellular products. The cell-based products segment is expected to account for the largest share in the global Regenerative medicine market in 2016. The increasing awareness about stem cell therapy, growing funding for new stem cell lines driving the growth of the cell-based products segment in the regenerative medicine market.

Based on therapy, the Regenerative medicine market is segmented into cell therapy, gene therapy, tissue engineering, and immunotherapy. Cell therapy segment is expected to account for the largest share in the global regenerative medicine market. The key drivers are increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies.

This market is also segmented by application. By application, orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is the fastest growing segment in the regenerative medicine market due to increasing incidences of cancer globally and increasing demand for cancer treatments.

Regenerative Medicines Market

The global Regenerative medicine market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America will continue to dominate the global Regenerative medicine market in the forecast period. However, Asia is expected to witness the highest CAGR, with the growth in this market centred at China, Japan and India. Increasing research activities in Asian countries, availability of funding for research, and the establishment of biobanks and research centers are some factors propelling market growth.

Orthopedic & Musculoskeletal Disorders, Dermatology, Cardiology, Central Nervous System Diseases will drive the growth of regenerative medicine market

Orthopedic & Musculoskeletal Disorders

The increasing prevalence of orthopedic diseases, rising aging population, increasing number of stem cell research projects and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders under both autologous and allogeneic cell therapies are the key drivers for the growth of this market.
According to WR Hambrecht & Co., a leading investment banking firm, the number of surgical procedures using orthobiologics and bone graft substitutes will continue to increase in the near future. Moreover, according to the U.S. Centers for Medicare and Medicaid Services, approximately 900,000 surgeries (which require bone regeneration) are performed annually in the U.S. Of these, spinal fusion (about 450,000 surgeries performed annually in the U.S.) was the most common surgery.

Dermatology

In dermatology, regenerative medicine is majorly used for tissue regeneration and healing of burns and chronic wounds. The treatment of burns and chronic wounds requires a speedy response, where skin grafting is required in most of the cases. Regenerative medicine helps in reducing the after-effects of general treatments which are carried out for burns, including scars and other skin infections.

Cardiology

Several companies are developing regenerative medicine technologies to rescue, replace, and help repair damaged heart tissues and revascularize heart tissue in and around areas of infarction.

Central Nervous System Diseases

CNS diseases include a wide array of developmental, degenerative, and traumatic neurological conditions in the brain and spinal cord. Disorders associated with the central nervous system, such as Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), multiple sclerosis (MS), and stroke, are caused by a loss or dysfunction in neurons and glial cells in the brain or spinal cord.

Critical questions the report answers:

  • Where will all these developments take the industry in the mid to long term?
  • What are the upcoming industry applications for biobanking?

Ethical concerns with the use of embryonic stem cell for R&D is a major factor restraining the growth of the market. Research in regenerative medicine necessitates the use of animals and humans in gene therapy studies that involve the recombination of genes and stem cell research therapies. These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs that may harm animals and humans. In addition, stem cell research studies use human embryos for clinical applications that often lead to the destruction of the embryos.

In order to monitor these activities, strict regulations have been formulated by ethical authorities such as the Human Tissue Authority (HTA), Human Fertilization and Embryology Authority (HFEA), Medicines, Healthcare Products Regulatory Agency (MHRA), and Central Ethics Committee for Stem Cell Research. Ethical concerns on the use of cells for research are restricting cell biology research to a great extent in various countries across the globe.

The key players in the cell-based products segment are Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 12)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 15)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Market Share Estimation
           2.3.1 Key Data From Secondary Sources
           2.3.2 Key Data From Primary Sources
           2.3.3 Assumptions for the Study

3 Executive Summary (Page No. - 22)

4 Premium Insights (Page No. - 25)
    4.1 Regenerative Medicine: Market Overview
    4.2 Geographic Analysis: Regenerative Medicine Market, By Therapy, 2016
    4.3 Geographical Snapshot of the Regenerative Medicine Market

5 Market Overview (Page No. - 28)
    5.1 Introduction
    5.2 Market Dynamics
    5.3 Drivers
           5.3.1 Government & Private Funding to Support the Development of Regenerative Medicine
           5.3.2 Rising Prevalence of Chronic Diseases and Genetic Disorders
           5.3.3 Increase in Global Healthcare Expenditure
           5.3.4 Rapid Growth in the Aging Population
           5.3.5 Increase in Corporate Partnerships to Accelerate Development and Commercialization of Regenerative Medicine
    5.4 Restraints
           5.4.1 Ethical Concerns With the Use of Embryonic Stem Cell for R&D
           5.4.2 Lack of Clear Regulatory Guidelines
    5.5 Opportunities
           5.5.1 Rising Demand for Organ Transplantation
           5.5.2 Strong Product Pipeline

6 Global Regenerative Medicine Market, By Product (Page No. - 36)
    6.1 Introduction
    6.2 Cell-Based Products
           6.2.1 Allogeneic Products
           6.2.2 Autologous Products
    6.3 Acellular Products

7 Global Regenerative Medicine Market, By Therapy (Page No. - 44)
    7.1 Introduction
    7.2 Cell Therapy
    7.3 Tissue Engineering
    7.4 Immunotherapy
    7.5 Gene Therapy

8 Regenerative Medicine Market, By Application (Page No. - 52)
    8.1 Introduction
    8.2 Orthopedic & Musculoskeletal Disorders
    8.3 Dermatology
    8.4 Cardiology
    8.5 Central Nervous System Diseases
    8.6 Oncology
    8.7 Diabetes
    8.8 Other Applications

9 Global Regenerative Medicine Market, By Region (Page No. - 63)
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 U.K.
           9.3.3 France
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 Rest of Europe (RoE)
    9.4 Asia-Pacific
    9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. - 102)
     10.1 Overview
     10.2 Market Ranking
     10.3 Competitive Situation and Trends
               10.3.1 Acquisitions
               10.3.2 Partnerships
               10.3.3 Regulatory Approvals
               10.3.4 New Product Developments
               10.3.5 Others

11 Company Profiles (Page No. - 111)
(Overview, Financial*, Products & Services, Strategy, and Developments)
     11.1 Acelity L.P. Inc. (KCI Licensing)
     11.2 Nuvasive, Inc.
     11.3 Vericel Corporation
     11.4 Osiris Therapeutics, Inc.
     11.5 Integra Lifesciences Corporation
     11.6 Stryker Corporation
     11.7 Medtronic PLC 
     11.8 Cook Biotech Incorporated
     11.9 Organogenesis Inc.
     11.10 Japan Tissue Engineering Co., Ltd. (Subsidiary of Fujifilm Holdings Corporation)

*Details Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 130)
     12.1 Insights From Industry Experts
     12.2 Discussion Guide
     12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.4 Introducing RT: Real-Time Market Intelligence
     12.5 Available Customizations
     12.6 Related Reports
     12.7 Author Details


List of Tables (87 Tables)

Table 1 Key Corporate Partnerships, 2016
Table 2 Gene Therapy Products in Clinical Trials, 2016
Table 3 Cell and Gene Therapy Clinical Product Pipeline, 2016
Table 4 Global Market Size, By Product, 2014–2021 (USD Billion)
Table 5 Cell-Based Products Market Size, By Region, 2014–2021 (USD Billion)
Table 6 Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 7 Allogeneic Products Market Size, By Region, 2014–2021 (USD Billion)
Table 8 Autologous Products Market Size, By Region, 2014–2021 (USD Billion)
Table 9 Acellular Products Market Size, By Region, 2014–2021 (USD Billion)
Table 10 Global Market Size, By Therapy, 2014–2021 (USD Billion)
Table 11 Stem Cell Therapies in Phase Iii Development, 2016
Table 12 Cell Therapy Market Size, By Region, 2014-2021 (USD Billion)
Table 13 Tissue Engineering Market Size, By Region, 2014-2021 (USD Billion)
Table 14 Immunotherapy Market Size, By Region, 2014-2021 (USD Billion)
Table 15 Gene Therapies in Clinical Trials, 2016
Table 16 Gene Therapy Market Size, By Region, 2014-2021 (USD Billion)
Table 17 Number of Clinical Trials for Regenerative Medicine, By Therapeutic Category (2016)
Table 18 Number of Clinical Trials for Regenerative Medicine, By Phase (2016)
Table 19 Market Size, By Application, 2014–2021 (USD Billion)
Table 20 Orthopedic & Musculoskeletal Disorders Market Size, By Region, 2014–2021 (USD Billion)
Table 21 Dermatology Market Size, By Region, 2014–2021 (USD Billion)
Table 22 Cardiology Market Size, By Region, 2014–2021 (USD Billion)
Table 23 Central Nervous System Diseases Market Size, By Region, 2014–2021 (USD Billion)
Table 24 Cancer Patients (Global), By Cancer Type, 2015–2035
Table 25 Oncology Market Size, By Region, 2014–2021 (USD Billion)
Table 26 Diabetes Market Size, By Region, 2014–2021 (USD Billion)
Table 27 Other Applications Market Size, By Region, 2014–2021 (USD Billion)
Table 28 Global Market Size, By Region, 2014–2021 (USD Billion)
Table 29 North America: Market Size, By Country, 2014–2021 (USD Billion)
Table 30 North America: Market Size, By Product, 2014–2021 (USD Billion)
Table 31 North America: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 32 North America: Market Size, By Application, 2014–2021 (USD Billion)
Table 33 North America: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 34 U.S.: Market Size, By Product, 2014–2021 (USD Billion)
Table 35 U.S.: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 36 U.S.: Market Size, By Application, 2014–2021 (USD Billion)
Table 37 U.S.: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 38 Canada: Market Size, By Product, 2014–2021 (USD Billion)
Table 39 Canada: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 40 Canada: Market Size, By Application, 2014–2021 (USD Billion)
Table 41 Canada: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 42 Europe: Market Size, By Country, 2014–2021 (USD Billion)
Table 43 Europe: Market Size, By Product, 2014–2021 (USD Billion)
Table 44 Europe: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 45 Europe: Market Size, By Application, 2014–2021 (USD Billion)
Table 46 Europe: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 47 Germany: Market Size, By Product, 2014–2021 (USD Billion)
Table 48 Germany: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 49 Germany: Market Size, By Application, 2014–2021 (USD Billion)
Table 50 Germany: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 51 U.K.: Market Size, By Product, 2014–2021 (USD Billion)
Table 52 U.K.: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 53 U.K.: Market Size, By Application, 2014–2021 (USD Billion)
Table 54 U.K.: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 55 France: Market Size, By Product, 2014–2021 (USD Billion)
Table 56 France: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 57 France: Market Size, By Application, 2014–2021 (USD Billion)
Table 58 France: Market Size, By Therapy, 2014–2021 (USD Billion)
Table 59 Italy: Market Size, By Product, 2014–2021 (USD Billion)
Table 60 Italy: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 61 Italy: Regenerative Medicine Market Size, By Application, 2014–2021 (USD Billion)
Table 62 Italy: Regenerative Medicine Market Size, By Therapy, 2014–2021 (USD Billion)
Table 63 Spain: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Table 64 Spain: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 65 Spain: Regenerative Medicine Market Size, By Application, 2014–2021 (USD Billion)
Table 66 Spain: Regenerative Medicine Market Size, By Therapy, 2014–2021 (USD Billion)
Table 67 RoE: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Table 68 RoE: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 69 RoE: Regenerative Medicine Market Size, By Application, 2014–2021 (USD Billion)
Table 70 RoE: Regenerative Medicine Market Size, By Therapy, 2014–2021 (USD Billion)
Table 71 Asia-Pacific: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Table 72 Asia: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 73 Asia-Pacific: Regenerative Medicine Market Size, By Application, 2014–2021 (USD Billion)
Table 74 Asia-Pacific: Regenerative Medicine Market Size, By Therapy, 2013–2021 (USD Billion)
Table 75 RoW: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Table 76 RoW: Cell-Based Products Market Size, By Type, 2014–2021 (USD Billion)
Table 77 RoW: Regenerative Medicine Market Size, By Application, 2014–2021 (USD Billion)
Table 78 RoW: Regenerative Medicine Market Size, By Therapy, 2014–2021 (USD Billion)
Table 79 Ranking of Major Players in the Global Cell-Based Regenerative Medicine Market (2015)
Table 80 Ranking of Major Players in the Global Acellular Regenerative Medicine Market (2015)
Table 81 Key Products in the Cell-Based Regenerative Medicine Market (2015)
Table 82 Key Products in the Acellular Regenerative Medicine Market (2015)
Table 83 Acquisitions, 2014–2017
Table 84 Partnerships, 2014–2016
Table 85 Regulatory Approvals, 2014–2016
Table 86 New Product Developments, 2013–2016
Table 87 Others, 2014–2016
 
 
List of Figures (38 Figures)
 
Figure 1 Research Design
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Cell-Based Products to Lead the Market During the Forecast Period
Figure 7 Cell Therapy to Dominate the Regenerative Medicine Market By 2021
Figure 8 Global Regenerative Medicine Market, By Application, 2016 vs 2021
Figure 9 North America to Lead the Regenerative Medicine Market During  the Forecast Period
Figure 10 Global Regenerative Medicine Market to Register High, Double-Digit Growth From 2016 to 2021
Figure 11 Cell Therapy Segment to Dominate the Regenerative Medicine Market in 2016
Figure 12 Asia-Pacific to Be the Fastest-Growing Region in the Forecast Period
Figure 13 Global Regenerative Medicine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 14 Global Regenerative Medicine Market Segmentation, By Product
Figure 15 Cell-Based Products to Command the Largest Share of the Global Regenerative Medicine Market in 2016
Figure 16 Cell-Based Products Market Segmentation, By Type
Figure 17 Cell Therapy to Dominate the Regenerative Medicine Market During the Forecast Period
Figure 18 Orthopedic & Musculoskeletal Disorders Segment to Dominate the Regenerative Medicine Applications Market in 2016
Figure 19 Number of Diabetes Cases, 2015 vs 2040 (Million)
Figure 20 North America: Regenerative Medicine Market Snapshot
Figure 21 North America: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Figure 22 U.S.: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Figure 23 Europe: Regenerative Medicine Market Snapshot
Figure 24 Europe: Regenerative Medicine Market Size, By Therapy, 2014–2021 (USD Billion)
Figure 25 Germany: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Figure 26 Asia-Pacific: Regenerative Medicine Market Snapshot
Figure 27 Asia-Pacific.: Regenerative Medicine Market Size, By Product, 2014–2021 (USD Billion)
Figure 28 Rest of the World: Regenerative Medicine Market Snapshot
Figure 29 RoW: Regenerative Medicine Market Size, By Therapy, 2014–2021 (USD Billion)
Figure 30 Leading Market Players Adopted Both Organic and Inorganic Growth Strategies Over the Last Four Years (2013–2017)
Figure 31 Battle for Market Share: New Product Launches & Product Enhancements are the Key Strategies
Figure 32 Acelity (KCI Licensing): Company Snapshot (2015)
Figure 33 Nuvasive, Inc.: Company Snapshot (2015)
Figure 34 Vericel Corporation: Company Snapshot (2015)
Figure 35 Osiris Therapeutics, Inc.: Company Snapshot (2014)
Figure 36 Integra Lifesciences Corporation: Company Snapshot (2015)
Figure 37 Medtronic PLC: Company Snapshot (2016)
Figure 38 Japan Tissue Engineering Co., Ltd: Company Snapshot (2015)


Request for detailed methodology, assumptions & how numbers were triangulated.

Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
BT 4419
Published ON
Feb, 2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved